Omalizumab 150 mg Injection
RxNorm 1657209

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1657209 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: omalizumab 150 mg Injection.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Omalizumab 150 mg Injection
Primary clinical definition
AUI:7251188
View
PSN
Omalizumab 150 mg Injection
AUI:7251194
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
Omalizumab 150 mg Injection
(Atom ID: 7251188)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
omalizumab 150 MG Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1657209
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7251188
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
1657209
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{1657207} 302379
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{1657207} 302379
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
150 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{1657207} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
PSNPrescribable

Prescribable Name (PSN):
Omalizumab 150 mg Injection
(Atom ID: 7251194)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
omalizumab 150 MG Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1657209
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7251194
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1657209
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Omalizumab Injection


Omalizumab injection is used to decrease the number of asthma attacks (sudden episodes of wheezing, shortness of breath, and trouble breathing) in adults and children 6 years of age and older with allergic asthma (asthma caused by inhaling substances such as dander, pollen, and dust mites) whose symptoms are not controlled with inhaled steroids. It is also used to treat nasal polyps (swelling of the lining of the nose) in adults whose symptoms are not controlled with inhaled steroids. Omalizumab is also used to treat chronic hives without a known cause that cannot successfully be treated with antihistamine medications such as diphenhydramine (Benadryl), cetirizine (Zyrtec), hydroxyzine (Vistaril), and loratadine (Claritin) in adults and children 12 years of age and older. Omalizumab is not used to treat other forms of hives or allergic conditions. Omalizumab injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes the symptoms of allergic asthma, nasal polyps, and hives.
[Learn More]


* Please review the disclaimer below.